Insider · SEC Form 4 filer

Seah Lim

Companies

Where they file as an insider

Emmaus Life Sciences (EMMA) Director Latest filing Sep 16, 2024

Track record

Did their buys beat the typical stock?

Open-market buys5
Quarters checked 6 months later0
Beat the typical stock —
Quarters too new to check0

Too soon to tell. None of their buys has a finished 6-month check yet.

Emmaus Life Sciences (EMMA) Bought Sep 16, 2024 · $800 · 20,000 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2024 and Mar 31, 2025.
Emmaus Life Sciences (EMMA) Bought Aug 25–Sep 5, 2023 · $28.1K · 113,800 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2023 and Mar 31, 2024.
Emmaus Life Sciences (EMMA) Bought Oct 9, 2022 · $2.79K · 25,400 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2022 and Jun 30, 2023.

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist